Veradermics, Incorporated is a clinical-stage biopharmaceutical company dedicated to addressing pervasive treatment challenges in aesthetic and medical dermatology. The company's primary focus is on pattern hair loss (PHL), a condition affecting millions of adults globally with limited FDA-approved systemic treatment options. Veradermics' lead product candidate is VDPHL01, a proprietary, oral, extended-release formulation of minoxidil. While immediate-release minoxidil is often used off-label for hair growth, VDPHL01 utilizes a gel matrix designed to deliver a steady, long-lasting release of the drug, maximizing hair growth efficacy while minimizing the peak blood concentrations associated with cardiovascular side effects. The company is advancing VDPHL01 through multiple Phase 3 clinical trials for both male and female pattern hair loss. Beyond its lead program, Veradermics is developing a pipeline of dermatological treatments, including VDMN, a dissolvable microarray patch for the immunotherapy of common warts, as well as therapies for alopecia areata (VDAA) and molluscum contagiosum (VDMC). As a pre-revenue, clinical-stage company, Veradermics does not yet generate product sales and relies on capital raised through equity offerings, including its February 2026 initial public offering, to fund its clinical trials and path toward commercialization.
